Drugs belonging to SGLT2 inhibitors class (Canagliflozin, Dapagliflozin and Empagliflozin) are well known to reduce the risk of heart disease and death in patients with diabetes. The same class of drugs are now known to reduce the risk of kidney disease progression in patients with diabetes, especially if they have proteinuria (condition of having more protein in urine). Large studies together involving more than 34000 patients have substantiated these claims.

In a new research called CREDENCE, Canagliflozin has been found to reduce progression of kidney disease in subjects with diabetic kidney disease. However, not all patients can use these drugs. Your doctor can help you understand the benefits and risks of these drugs.